Korean ginseng company, ILHWA Co Ltd, just announced the formation of U.S. subsidiary, ILHWA North America Inc. Korea’s groundbreaking ginseng company, ILHWA Co Ltd, just announced the formation of a wholly-owned U.S. subsidiary, ILHWA North America Inc, which is launching a high absorption ginseng extract utilizing a patented high yield enzyme fermented process. This unique ginseng extract promises to be a game changer in the ingredient market by delivering higher efficacy, consistent absorption, improved taste profile, plus a lower cost per use.
“Today, we are proud to announce yet another important breakthrough in ginseng technology,” said Gregg Noll, president of ILHWA North America. “Our researchers have found a way to resolve the three most important concerns of manufacturers and formulators with ginseng: increased efficacy, better taste, and lower cost.”
ILHWA Co Ltd, is a high tech pharmaceutical and nutraceutical company with 3 divisions: Ginseng, Pharmaceuticals and Beverages. Through continuous scientific research and development for more than four decades, Ilhwa has become the world leader in ginseng science.
They are fully KFDA compliant and GMP and ISO certified, holding numerous patents and the publications of 100’s of papers and clinical studies. In 2011, Ilhwa received KFDA approval for a “certified health claim” on it new enzyme fermented ginseng extract to claim “helps to manage blood glucose”. Ilhwa is the first ginseng company to receive this certification.
Noll continued, “It is the ideal time for Ilhwa to begin ILHWA North America Inc, as we introduce our patented high absorption ginseng extract, called “GinST 15”.